My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about SVNT

EAST BRUNSWICK, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the JP Morgan Healthcare Conference on Monday, January 11, 2010 at 2:30 p.m. Pacific Time. The conference is being held at Westin St. Francis Hotel in San Francisco, CA.

Individuals can access a live webcast of the presentation through the investor relations section of the company's web site www.savient.com. Following the live presentation, a replay of the webcast will be made available on the Company's web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

SVNT - G

SOURCE Savient Pharmaceuticals, Inc.

RELATED LINKS
http://www.savient.com